Platelet-derived growth factor receptors (PDGFRs) fusion genes involvement in hematological malignancies

- PDGFR Gene, Protein Structure and Functions.
- PDGFR Fusion Partners-Associated Hematological Malignancies.
- Functional Consequences of PDGFR Fusion Genes.
- Diagnosis of PDGFR Fusion Partners-Associated Hematological Malignancies.
- Development of Drugs for PDGFR Fusion Partners Involvement in Hematological malignancies.

PurposeTo investigate oncogenic platelet-derived growth factor receptor(PDGFR) fusion genes involvement in hematological malignancies, the advances in the PDGFR fusion genes diagnosis and development of PDGFR fusions inhibitors.MethodsLiterature search was done using terms “PDGFR and Fusion” or “PDGFR and Myeloid neoplasm” or 'PDGFR and Lymphoid neoplasm' or “PDGFR Fusion Diagnosis” or “PDGFR Fusion Targets” in databases including PubMed, ASCO.org, and Medscape.ResultsOut of the 36 fusions detected, ETV6(TEL)-PDGFRB and FIP1L1-PDGFRA fusions were frequently detected, 33 are as a result of chromosomal translocation, FIP1L1-PDGFRA and EBF1-PDGFRB are the result of chromosomal deletion and CDK5RAP2- PDGFRΑ is the result of chromosomal insertion. Seven of the 34 rare fusions have detectable reciprocals.ConclusionRNA aptamers are promising therapeutic target of PDGFRs and diagnostic tools of PDGFRs fusion genes. Also, PDGFRs have variable prospective therapeutic strategies including small molecules, RNA aptamers, and interference therapeutics as well as development of adaptor protein Lnk mimetic drugs.